News Sentiment

DMII sentiment intelligence

Drugs Made In America Acquisition II Corp. Ordinary Shares news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 47 Balanced news tone 44 relevant articles
Exchange NASDAQ United States
Sector Financial Services Market context
Industry Shell Companies Read-through group
Latest close 10.10 Week of 10 Jul 2026
Weighted tone 47/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Deals and strategy

87/100 classification confidence.

Company focus 44

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend active

+0.1% over one week, +0.2% over four weeks, trend active, and near fair-value range.

Latest direct headline Neutral

Drugs Made In America Acquisition (NASDAQ:DMAA) Trading Down 0.1% - Here's What Happened

Market Reaction

Balanced read

54/100 confidence

News tone and price action are not far from neutral.

Primary event Deals and strategy 87/100 classification
One-week reaction 0.1% Price digesting
Trend fit Trend active 0.2% over four weeks
Fair value 1.1% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 3
Neutral 33
Negative 8

Relevance

Why the article matched

Direct first
Direct company coverage 44
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 11
TradingView 7
Meyka 4
MarketBeat 2
www.marketscreener.com 2
Investing.com 2
TipRanks 2
Market source 2

Event Lens

What the news is about

Classified themes
Deals and strategy 34
Market update 9
Earnings 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 44
TradingView Direct company coverage

Price to sales forward of Drugs Made In America Acquisition II Corp. – NASDAQ:DMII

The article focuses on the "Price to sales forward" metric for Drugs Made In America Acquisition II Corp. (NASDAQ: DMII). It provides basic financial and market information for the company, indicating that the market is currently closed with no trades. The content appears to be a

Tone
Neutral 50/100
Event
Deals and strategy
Published
29 Jun 2026 13:11
Source
TradingView
Intellectia AI Direct company coverage

DMII Financials: Revenue Breakdown, Margins & Competitor Comparison

This article provides a financial overview of Drugs Made In America Acquisition II Corp (DMII), detailing its profitability ratios, including Return on Equity, and comparing its market capitalization with competitors like RMR and BCSS. It notes that DMII's gross, operating, and n

Tone
Neutral 50/100
Event
Deals and strategy
Published
27 Jun 2026 22:10
Source
Intellectia AI
TradingView Direct company coverage

Price to book forward of Drugs Made In America Acquisition II Corp. – NASDAQ:DMIIR

This article provides financial information for Drugs Made In America Acquisition II Corp. (NASDAQ: DMIIR), specifically focusing on its price-to-book forward ratio. The content appears to be a stub or a section from a larger financial data platform.

Tone
Neutral 50/100
Event
Deals and strategy
Published
26 Jun 2026 12:08
Source
TradingView
GuruFocus Direct company coverage

HEIGHTS CAPITAL MANAGEMENT, INC's Drugs Made In America Acquisition II Corp(DMIIU) Holding History

This article details HEIGHTS CAPITAL MANAGEMENT, INC's historical holdings in Drugs Made In America Acquisition II Corp (DMIIU). As of March 31, 2026, the firm holds 0 shares of DMIIU, having made one purchase and one sale of 519,400 shares each, resulting in an estimated gain of

Tone
Neutral 50/100
Event
Deals and strategy
Published
15 May 2026 22:09
Source
GuruFocus
The Globe and Mail Direct company coverage

Drugs Made In America Acquisition Updates Executive Compensation Agreements

Drugs Made In America Acquisition II Corp. (DMII) has updated its executive compensation agreements. Saleem Elmasri, CFO, will now receive 175,000 ordinary shares, while Roger Bendelac, CEO, will receive a monthly salary of $4,500 and 250,000 ordinary shares upon a definitive agr

Tone
Positive 62/100
Event
Deals and strategy
Published
29 Apr 2026 23:09
Source
The Globe and Mail
Stock Titan Direct company coverage

Drugs Made In America (NASDAQ: DMAA) details SPAC cash, LOI and risks

Drugs Made In America Acquisition Corp. (DMAA), a SPAC, has filed its annual report detailing its search for a merger target. The company currently holds $231.15 million in its trust account and reported a net income of $5.94 million in 2025 from interest on these investments. DM

Tone
Neutral 50/100
Event
Deals and strategy
Published
15 Apr 2026 21:40
Source
Stock Titan
Stock Titan Direct company coverage

Drugs Made In America Acquisition II (DMII) logs $4.2M income, flags going-concern risk

Drugs Made In America Acquisition II (DMII), a blank check company, reported a net income of $4.187 million for 2025, primarily from interest on its $500 million trust account investments. However, the company faces substantial doubt about its ability to continue as a going conce

Tone
Negative 29/100
Event
Deals and strategy
Published
15 Apr 2026 20:08
Source
Stock Titan
www.marketscreener.com Direct company coverage

Drugs Made In America Acquisition II Corp. Auditor Raises 'Going Concern' Doubt

Drugs Made In America Acquisition II Corp. (DMII) recently had its auditor, Malone & Bailey, PLLC, express doubt about the company's ability to continue as a going concern. This assessment was made after the company filed its 10-K report on April 15, 2026, for the fiscal year end

Tone
Negative 19/100
Event
Deals and strategy
Published
12 Apr 2026 19:10
Source
www.marketscreener.com
Investing.com Direct company coverage

Drugs Made in America Acquisition Corp. signs LOI for de-SPAC with Power Analytics

Drugs Made in America Acquisition Corp. (NASDAQ:DMAA) announced it has signed a letter of intent for a de-SPAC transaction with Power Analytics Global Corp., valuing the target company at approximately $1.0 billion. The transaction is subject to further negotiation and due dilige

Tone
Neutral 50/100
Event
Deals and strategy
Published
09 Apr 2026 09:12
Source
Investing.com
Meyka Direct company coverage

Drugs Made In America Acquisition II Corp. Unit (DMIIU) Competitors

This article provides a detailed comparison of Drugs Made In America Acquisition II Corp. Unit (DMIIU) with numerous competitors in the Financial Services sector. It presents a peer comparison table with financial metrics like price, market cap, P/E ratio, EPS, and dividend yield

Tone
Neutral 50/100
Event
Deals and strategy
Published
09 Apr 2026 01:09
Source
Meyka
Investing.com Canada Direct company coverage

Drugs Made In America Acquisition II Corp. enters $300,000 convertible note agreement

Drugs Made In America Acquisition II Corp. (DMIIU, DMII, DMIIR) has entered into a $300,000 interim convertible note agreement with Alpha Multi Family Office, carrying no interest and maturing in nine months. This note allows Alpha Multi Family Office to convert the principal int

Tone
Neutral 50/100
Event
Deals and strategy
Published
04 Apr 2026 22:39
Source
Investing.com Canada
Minichart Direct company coverage

Drugs Made In America Acquisition II Corp. Announces $1.4 Million Convertible Notes Financing Agreement with Alpha Multi Family Office

Drugs Made In America Acquisition II Corp. has secured a $1.4 million convertible notes financing agreement from S.E.E Capitals Ltd., with the funds allocated for operational and regulatory costs. The agreement includes provisions for potential share dilution if the investor conv

Tone
Negative 39/100
Event
Deals and strategy
Published
04 Apr 2026 22:09
Source
Minichart
TipRanks Direct company coverage

Drugs Made In America II Issues Interim Convertible Note

Drugs Made In America Acquisition II Corp. (DMII) has issued a new $300,000 interim convertible note on March 30, 2026, building upon a previous $150,000 bridge note from March 11, 2026, as part of a $1.4 million financing plan. This new note, maturing in nine months with no inte

Tone
Positive 63/100
Event
Deals and strategy
Published
03 Apr 2026 21:12
Source
TipRanks
TradingView Direct company coverage

Drugs Made In America Acquisition II Finalizes $1.4M Notes Deal, Adds $300K Interim Convertible

Drugs Made In America Acquisition II (DMII) has finalized a definitive agreement with Alpha Multi Family Office for a $1.4 million convertible notes financing. Concurrently, it issued a new $300,000 interim convertible note to provide immediate liquidity. Both agreements aim to s

Tone
Positive 65/100
Event
Deals and strategy
Published
03 Apr 2026 20:42
Source
TradingView
Stock Titan Direct company coverage

$300K zero‑interest note backs Drugs Made In America II (NASDAQ: DMII)

Drugs Made In America Acquisition II Corp. (DMII) secured a new $300,000 zero-interest Interim Convertible Note from Alpha Multi Family Office, part of a contemplated $1.4 million financing. This note matures in nine months and can convert into shares at a 35% discount post-merge

Tone
Neutral 50/100
Event
Deals and strategy
Published
03 Apr 2026 20:39
Source
Stock Titan
TipRanks Direct company coverage

Drugs Made in America Acquisition II Delays Annual Filing

Drugs Made in America Acquisition II Corp. (DMII) has announced a delay in filing its Form 10-K for the fiscal year ended December 31, 2025, due to complexities in compiling required financial statements. The company anticipates filing by April 15, 2026, and does not foresee sign

Tone
Neutral 50/100
Event
Deals and strategy
Published
01 Apr 2026 23:39
Source
TipRanks
Stock Titan Direct company coverage

DMII (NASDAQ: DMII) files 12b-25—expects to file 10-K by Apr 15, 2026

Drugs Made in America Acquisition II Corp. (DMII) has filed a Form 12b-25 with the SEC, indicating that it will be submitting its Form 10-K for the fiscal year ended December 31, 2025, later than the due date. The company stated that compiling the required financial statements an

Tone
Negative 37/100
Event
Deals and strategy
Published
01 Apr 2026 20:11
Source
Stock Titan
FinancialContent Direct company coverage

Drugs Made In America Acquisition II Corp. - Right (NQ: DMIIR)

This article provides a brief overview of Drugs Made In America Acquisition II Corp. - Right (DMIIR) stock, including its current price, trading volume, and performance metrics. It lists the stock at $0.0800, unchanged, with its last trade recorded on April 1, 2026, at 3:20 PM ED

Tone
Neutral 50/100
Event
Deals and strategy
Published
01 Apr 2026 19:39
Source
FinancialContent
Meyka Direct company coverage

Why Is Drugs Made In America Acquisition II Corp. Unit (DMIIU) Stock Down Today?

Drugs Made In America Acquisition II Corp. Unit (DMIIU) stock is currently down -0.10% at $10.02, indicating a negative investor sentiment. The stock is trading below both its 50-day and 200-day moving averages, suggesting short-term and long-term weakness. Meyka's AI assigns DMI

Tone
Neutral 50/100
Event
Deals and strategy
Published
24 Mar 2026 11:08
Source
Meyka
Meyka Direct company coverage

Why Is Drugs Made In America Acquisition II Corp. Ordinary Shares (DMII) Stock Down Today?

Drugs Made In America Acquisition II Corp. Ordinary Shares (DMII) stock is down 0.10% today, trading at $9.96 with significantly lower than average trading volume. The stock is below its 50-day moving average but above its 200-day moving average, suggesting short-term weakness bu

Tone
Neutral 50/100
Event
Deals and strategy
Published
23 Mar 2026 21:08
Source
Meyka
www.marketscreener.com Direct company coverage

14,375,000 Ordinary Shares of Drugs Made In America Acquisition II Corp. are subject to a Lock-Up Agreement Ending on 23-MAR-2026.

Approximately 14,375,000 ordinary shares of Drugs Made In America Acquisition II Corp. (DMII) are subject to a lock-up agreement that expires on March 23, 2026. This lock-up period began on September 24, 2025, and restricts the sale or transfer of these shares by the company's sp

Tone
Neutral 50/100
Event
Deals and strategy
Published
23 Mar 2026 00:10
Source
www.marketscreener.com
Stock Titan Direct company coverage

DMII Stock Price, News & Analysis

Drugs Made In Amer Acq Ii (DMII) is a blank check company listed on NASDAQ with a market capitalization of $653.1M. The stock last traded at $9.96, showing a 0.8% gain over the past year. Recent SEC filings include a planned $1.4M convertible note funding and a CEO change due to

Tone
Neutral 50/100
Event
Market update
Published
18 Mar 2026 18:39
Source
Stock Titan